BDNF and S100B in psychotic disorders: Evidence for an association with treatment responsiveness

Acta Neuropsychiatrica

Volumn 26, Issue 4, 2014, Pages 223-229

  Van De Kerkhof, Noortje W A ^a,b   Fekkes, Durk ^b   Van Der Heijden, Frank M M A ^a   Verhoeven, Willem M A ^a,b  

^a VINCENT VAN GOGH INSTITUTE FOR PSYCHIATRY   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

BDNF; psychosis; S100B; symptomatology; treatment response

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; NEUROLEPTIC AGENT; PROTEIN S100B; BRAIN-DERIVED NEUROTROPHIC FACTOR, HUMAN; S100B PROTEIN, HUMAN;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DSM-IV; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEGATIVE SYNDROME; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; PSYCHOSIS; SCORING SYSTEM; SYMPTOM; TREATMENT RESPONSE; ADOLESCENT; AGED; BLOOD; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; PSYCHOTIC DISORDERS; TREATMENT OUTCOME; YOUNG ADULT; COMPREHENSIVE ASSESSMENT OF SYMPTOMS AND HISTORY; DISEASE ASSOCIATION; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NERVE CELL PLASTICITY; PROTEIN BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; BRAIN-DERIVED NEUROTROPHIC FACTOR; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; S100 CALCIUM BINDING PROTEIN BETA SUBUNIT; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84903904212     PISSN: 09242708     EISSN: 16015215     Source Type: Journal    
DOI: 10.1017/neu.2013.59     Document Type: Article

References (42)

1. Van Haren NEM, Cahn W, Pol HEH, Kahn RS. Schizophrenia as a progressive brain disease. Eur Psychiatry 2008a; 23: 245-254
2. Owen MJ, O'donovan MC, Thapar A, Craddock N. Neurodevelopmental hypothesis of schizophrenia. Br J Psychiatry 2011; 198: 173-175
3. Gogtay N, Giedd JN, Lusk L et al. Dynamic mapping of human cortical development during childhood through early adulthood. Proc Natl Acad Sci USA 2004; 101: 8174-8179
4. Shaw P, Kabani NJ, Lerch JP et al. Neurodevelopmental trajectories of the human cerebral cortex. J Neurosci 2008; 28: 3586-3594
5. Arango C, Moreno C, MartíNEZ S et al. Longitudinal brain changes in early-onset psychosis. Schizophr Bull 2008; 34: 341-353
6. Van Haren NEM, Hulshoff POL HE, Schnack HG et al. Progressive brain volume loss in schizophrenia over the course of the illness: Evidence of maturational abnormalities in early adulthood. Biol Psychiatry 2008b; 63: 106-113
7. Mcglashan TH, Hoffman RE. Schizophrenia as a disorder of developmentally reduced synaptic connectivity. Arch Gen Psychiatry 2000; 57: 637-648
8. Durany N, Thome J. Neurotrophic factors and the pathophysiology of schizophrenic psychoses. Eur Psychiatry 2004; 19: 326-337
9. Pan W, Banks WA, Fasold MB, Bluth J, Kastin AJ. Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacology 1998; 37: 1553-1561
10. Marchi N, Cavaglia M, Fazio V, Bhudia S, Hallene K, Janigro D. Peripheral markers of blood-brain barrier damage. Clin Chim Acta 2004; 342: 1-12
11. Karege F, Schwald M, Cisse M. Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets. Neurosci Lett 2002; 328: 261-264
12. Pillai A, Kale A, Joshi S et al. Decreased BDNF levels in CSF of drug-naive first-episode psychotic subjects: Correlation with plasma BDNF and psychopathology. Int J Neuropsychopharmacol 2010; 13: 535-539
13. Rothermundt M, Falkai P, Ponath G et al. Glial cell dysfunction in schizophrenia indicated by increased S100B in the CSF. Mol Psychiatry 2004a; 9: 897-899
14. Steiner J, Bogerts B, Schroeter ML, Bernstein H. S100B protein in neurodegenerative disorders. Clin Chem LabMed 2011; 49: 409-424
15. Pirildar S-, Gönül AS, Taneli F, Akdeniz F. Low serum levels of brain-derived neurotrophic factor in patients with schizophrenia do not elevate after antipsychotic treatment. Prog Neuro-Psychopharmacol Biol Psychiatry 2004; 28: 709-713
16. Twiss JL, Chang JH, Schanen NC. Pathophysiological mechanisms for actions of the neurotrophins. Brain Pathol 2006; 16: 320-332
17. Green MJ, Matheson SL, Shepherd A, Weickert CS, Carr VJ. Brain-derived neurotrophic factor levels in schizophrenia: A systematic review with meta-Analysis. Mol Psychiatry 2011; 16: 960-972
18. Buckley PF, Pillai A, Howell KR. Brain-derived neurotrophic factor: Findings in schizophrenia. Curr Opin Psychiatry 2011; 24: 122-127
19. Chen DC, Wang J, Wang B et al. Decreased levels of serum brain-derived neurotrophic factor in drug-nai?ve first-episode schizophrenia: Relationship to clinical phenotypes. Psychopharmacology 2009; 207: 375-380
20. Jindal RD, Pillai AK, Mahadik SP, Eklund K, Montrose DM, Keshavan MS. Decreased BDNF in patients with antipsychotic nai?ve first episode schizophrenia. Schizophr Res 2010; 119: 47-51
21. Toyooka K, Asama K, Watanabe Y et al. Decreased levels of brain-derived neurotrophic factor in serum of chronic schizophrenic patients. Psychiatry Res 2002; 110: 249-257
22. Pedrini M, Chendo I, Grande I et al. Serum brain-derived neurotrophic factor and clozapine daily dose in patients with schizophrenia: A positive correlation. Neurosci Lett 2011; 491: 207-210
23. Schä FER BW, Heizmann CW. The S100 family of EF-hand calcium-binding proteins: Functions and pathology. Trends Biochem Sci 1996; 21: 134-140
24. Donato R. S100: A multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol 2001; 33: 637-668
25. Lara DR, Gama CS, Belmonte-DE-ABREU P et al. Increased serum S100B protein in schizophrenia: A study in medication-free patients. J Psychiatr Res 2001; 35: 11-14
26. Rothermundt M, Ponath G, Glaser T, Hetzel G, Arolt V. S100B serum levels and long-Term improvement of negative symptoms in patients with schizophrenia. Neuropsychopharmacology 2004b; 29: 1004-1011
27. Rothermundt M, Ahn JN, JöRGENS S. S100B in schizophrenia: An update. Gen Physiol Biophys 2009; 28 : F76-F81
28. Ling S, Tang Y, Jiang F et al. Plasma S-100B protein in Chinese patients with schizophrenia: Comparison with healthy controls and effect of antipsychotics treatment. J Psychiatr Res 2007; 41: 36-42
29. Sarandol A, Kirli S, Akkaya C, Altin A, Demirci M, Sarandol E. Oxidative-Antioxidative systems and their relation with serum S100 B levels in patients with schizophrenia: Effects of short term antipsychotic treatment. Prog Neuro-Psychopharmacol Biol Psychiatry 2007; 31: 1164-1169
30. Pedersen A, Diedrich M, Kaestner F et al. Memory impairment correlates with increased S100B serum concentrations in patients with chronic schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry 2008; 32: 1789-1792
31. Andreasen NC, Flaum MC, Arndt S. The comprehensive assessment of symptoms and history (CASH): An instrument for assessing diagnosis and psychopathology. Arch Gen Psychiatry 1992; 49: 615-623
32. Kay SR, Fiszbein A, Opfer LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261-276
33. Guy W. ECDEU Assessment Manual for Psychopharmacology, REVISED. Bethesda: National Institute of Mental Health, 1976
34. Post RM. Role of BDNF in bipolar and unipolar disorder: Clinical and theoretical implications. J Psychiatr Res 2007; 41: 979-990
35. Schroeter ML, Steiner J. Elevated serum levels of the glial marker protein S100B are not specific for schizophrenia or mood disorders. Mol Psychiatry 2009; 14: 235-236
36. Gonzá LEZ-PINTO A, Mosquera F, Palomino A et al. Increase in brain-derived neurotrophic factor in first episode psychotic patients after treatment with atypical antipsychotics. Int Clin Psychopharmacol 2010; 25: 241-245
37. Qi LY, Xiu MH, Chen DC et al. Increased serum S100B levels in chronic schizophrenic patients on long-Term clozapine or typical antipsychotics. Neurosci Lett 2009; 462: 113-117
38. Nasrallah H, Tandon R, Keshavan M. Beyond the facts in schizophrenia: Closing the gaps in diagnosis, pATHOPHYSIOLOGY, aND treatment. Epidemiol Psychiatr Sci 2011; 20: 317-327
39. Bromet EJ, Kotov R, Fochtmann LJ et al. Diagnostic shifts during the decade following first admission for psychosis. Am J Psychiatry 2011; 168: 1186-1194
40. Verhoeven WMA, Tuinier S, Van Der BURGT I. Top-down or bottom-up: Contrasting perspectives on psychiatric diagnoses. Biologics 2008; 2: 409-417
41. Van OS J, Kapur S. Schizophrenia. Lancet 2009; 374: 635-645
42. Linscott RJ, Van OS J. Systematic reviews of categorical versus continuum models in psychosis: Evidence for discontinuous subpopulations underlying a psychometric continuum. Implications for DSM-V, Dsm-VI, aND DSMVII. Annu Rev Clin Psychol 2010; 6: 391-419